Sharon Alterio - CR Bard Group Vice President
President
Ms. Sharon M. Luboff is Group Vice President of C R Bard Inc. She joined Bard in 2004 as President of Bard Medical Division. In 2009 Ms. Luboff was promoted to Group Vice President with responsibility for Bards international businesses and in 2012 she assumed additional responsibility for Bard Medical Division. In July 2013 Ms. Luboff assumed responsibility for Corporationrationrate Marketing Reimbursement Healthcare Economics and Business Development and Strategy. Prior to joining Bard Ms. Luboff held positions at Baxter Healthcare including Vice President Global Therapeutic Marketing for its Renal Division. since 2009.
| Age | 51 |
| Tenure | 15 years |
| Phone | 908 277-8000 |
| Web | www.crbard.com |
CR Bard Management Efficiency
CR Bard's management efficiency ratios could be used to measure how well CR Bard manages its routine affairs as well as how well it operates its assets and liabilities.The company has 1.64 B in debt with debt to equity (D/E) ratio of 81.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. CR Bard has a current ratio of 1.69, which is typical for the industry and considered as normal. Debt can assist CR Bard until it has trouble settling it off, either with new capital or with free cash flow. So, CR Bard's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CR Bard sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BCR to invest in growth at high rates of return. When we think about CR Bard's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Richard Rodier | Toro Co | 64 | |
| Courtland Pearson | Lifevantage | N/A | |
| Renee Peterson | Toro Co | 62 | |
| Bradley Hamilton | Toro Co | 56 | |
| Darren Redetzke | Toro Co | 56 | |
| Amy Dahl | Toro Co | 50 | |
| Peitro Giraffa | Hanover Foods | 62 | |
| Michelle ObornVirchow | Lifevantage | 44 | |
| Thomas Larson | Toro Co | 58 | |
| Blake Grams | Toro Co | 53 | |
| Richard Parod | Toro Co | 63 | |
| Michael Drazan | Toro Co | 55 | |
| Philip Burkart | Toro Co | 54 | |
| Judy Altmaier | Toro Co | 55 | |
| Jody Christy | Toro Co | 52 | |
| David Alkire | Toro Co | 54 | |
| Gary Knisely | Hanover Foods | 75 | |
| Timothy Dordell | Toro Co | 55 | |
| Kurt Svendsen | Toro Co | 58 | |
Management Performance
| Return On Equity | 0.0034 | |||
| Return On Asset | 0.0012 |
CR Bard Leadership Team
Elected by the shareholders, the CR Bard's board of directors comprises two types of representatives: CR Bard inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BCR. The board's role is to monitor CR Bard's management team and ensure that shareholders' interests are well served. CR Bard's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CR Bard's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Beasley, Group President | ||
| Patricia Christian, Vice President - Quality, Regulatory and Medical Affairs | ||
| Sharon Alterio, Group Vice President | ||
| Todd Garner, Vice President - Investor Relations | ||
| Marc Breslawsky, Independent Director | ||
| John Weiland, President, COO and Director | ||
| John DeFord, Senior Vice President - Science, Technology and Clinical Affairs | ||
| Frank Lupisella, Principal Accounting Officer, VP and Controller | ||
| Betty Larson, Vice President Human Resources. | ||
| John Groetelaars, Group Vice President | ||
| Tony White, Independent Director | ||
| Gerard Porreca, Vice President - Quality, Regulatory and Medical Affairs | ||
| Robert Davis, Director | ||
| Anthony Welters, Independent Director | ||
| Gail Naughton, Independent Director | ||
| John Kelly, Independent Director | ||
| Tommy Thompson, Independent Director | ||
| Samrat Khichi, Senior Vice President General Counsel, Secretary | ||
| Sharon Luboff, Group Vice President | ||
| Herbert Henkel, Lead Independent Director | ||
| Christopher Holland, CFO and Sr. VP | ||
| David Melcher, Director | ||
| Jim Beasley, Group Pres | ||
| Timothy Collins, Group Pres | ||
| Timothy Ring, Chairman, CEO and Chairman of Executive Committee | ||
| David Barrett, Independent Director |
BCR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CR Bard a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0034 | |||
| Return On Asset | 0.0012 | |||
| Profit Margin | 0 % | |||
| Operating Margin | 26.18 % | |||
| Current Valuation | 24.77 B | |||
| Shares Outstanding | 72.89 M | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 81.93 % | |||
| Number Of Shares Shorted | 1.05 M | |||
| Price To Earning | 43.69 X |
Pair Trading with CR Bard
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CR Bard position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CR Bard will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Prudential Financial could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prudential Financial when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prudential Financial - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prudential Financial to buy it.
The correlation of Prudential Financial is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prudential Financial moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prudential Financial moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prudential Financial can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the CR Bard information on this page should be used as a complementary analysis to other CR Bard's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in BCR Stock
If you are still planning to invest in CR Bard check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CR Bard's history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |